Search for: [Abstract = "of AE, with effectiveness proven by high\- or moderate quality scientific studies, and reimbursed. Among medicinal products licensed for use in Poland, yet in diseases other than atopic eczema, there were 51 preparations of 7 active substances \(betamethasone dipropionate, mometasone furoate, hydrocortisone butyrate, clobetasol propionate, azathioprine, loratadine, fexofenadine\), and 24 house dust mite allergy vaccines for immunotherapy with efficacy in the treatment of AE proven in high\- or moderate quality clinical trials. Among drugs recommended by expert bodies for the treatment of allergic contact dermatitis \(ACD\), 148 medicinal products with 26 active substances, and 20 emollients were licensed for use in Poland. Forty preparations containing 12 active substances, as well as 3 emollients were officially registered for treating this condition. None of the drugs which were both recommended by experts for treating ACD and licensed to Polish market contained active substances, whose effectiveness has been proven in high\- or moderate quality clinical trials. Consequently, none of the 11 drugs reimbursed in the indication \"allergic contact dermatitis\" \(4 active substances\) contained a substance with efficacy confirmed in clinical studies of at least moderate quality. Among medicinal products available in Poland, but not registered for the treatment of ACD, there were 5 medicinal"]

Number of results: 2